Φορτώνει......
Current state of immunotherapy for non-small cell lung cancer
Lung cancer is the leading cause of cancer mortality and non-small cell lung cancer (NSCLC) accounts for more than 85% of all lung cancers. Platinum-based doublet chemotherapy is the standard first-line treatment for metastatic NSCLC when genomic testing reveals no targetable alteration such as epid...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Transl Lung Cancer Res |
|---|---|
| Κύριοι συγγραφείς: | , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
AME Publishing Company
2017
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5420529/ https://ncbi.nlm.nih.gov/pubmed/28529902 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2017.03.01 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|